【摘 要】
：
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans
【机 构】
：
Albany Nephrology Pharmacy (ANephRx) Group, Albany, NY;Nephrology Pharmacy Associates, Inc.,Ann Arbo
【出 处】
：
2013年中国肾性贫血治疗专家共识研讨会
论文部分内容阅读
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans (ID).The rate of type 1 AE to iron sucrose (IS) and sodium ferric gluconate (SFG) relative to ID is unclear.We used the US Food and Drug Administrations Freedom of Information (FOI) surveillance database to compare the type 1 AE profiles for the three intravenous iron preparations available in the United States.Methods.We tabulated reports received by the FOI database between January 1997 and September 2002, and calculated 100 mg dose equivalents for the treated population for each agent.We developed four clinical categories describing hypersensitivity AE (anaphylaxis, anaphylactoid reaction, urticaria and angioedema) and an algorithm describing anaphylaxis, for specific analyses.Results.All-event reporting rates were 29.2, 10.5 and 4.2 reports/million 100mg dose equivalents, while all-fatal-event reporting rates were 1.4, 0.6 and 0.0 reports/million 100mg dose equivalents for ID, SFG and IS, respectively.ID had the highest reporting rates in all four clinical categories and the anaphylaxis algorithm.SFG had intermediate reporting rates for urticaria, anaphylactoid reaction and the anaphylaxis algorithm, and a zero reporting rate for the anaphylaxis clinical category.IS had either the lowest or a zero reporting rate in all clinical categories/algorithm.Conclusions.These findings confirm a higher risk for AE, especially serious type 1 reactions, with ID therapy than with newer intravenous iron products and also suggest that IS carries the lowest risk for hypersensitivity reactions.
其他文献
Background.Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients.However, the optimal
Iron deficiency limits the efficacy of recombinant human erythropoietin (rhEPO) therapy in end-stage renal disease (ESRD)patients.Functional iron deficiency occurs with serum ferritin >500 ng/ml and/o
Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis.Ferumoxytol is a novel i
Background: Serum ferritin, frequently used as a marker of iron status in individuals with chronic kidney disease, is also an inflammatory marker.The concurrent combination of high serum ferritin and
Background and objectives: As well as being a marker of body iron stores, serum ferritin (sFerritin) has also been shown to be a marker of inflammation in hemodialysis (HD) patients.The aim of this st
铁是合成血红蛋白的基本原料.流行病学及临床的研究证实在慢性肾脏病(CKD)贫血患者中常常存在一定程度的铁缺乏[1,2],铁缺乏也是导致红细胞刺激剂(ESA)治疗反应差的主要原因,予以充足的铁补充 ,不仅可以明显改善贫血,还可以减少ESA的使用剂量,甚至在未使用ESA的情况下也能改善贫血[3,4].因此对于CKD贫血患者需常规进行铁状态的评价,搜寻导致铁缺乏的原因.并根据患者的铁状态予以相应的铁剂补
Introduction Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree
Introduction Despite major recent therapeutic improvements, septic shock remains a leading cause of mortality in intensive care patients [1].For more than a decade, it has been advocated [2,3] that th
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who